Asfiled with the Securities and Exchange Commission on June 16, 2022

RegistrationNo. 333-

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORMS-1

REGISTRATIONSTATEMENT UNDER THE SECURITIES ACT OF 1933

LUCIDDIAGNOSTICS INC.

(ExactName of Registrant as Specified in Its Charter)

3841

(PrimaryStandard Industrial Classification Code Number)

OneGrand Central Place, Suite 4600

NewYork, New York 10165

(212)949-4319

(Address,Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

LishanAklog, M.D.

Chairmanand Chief Executive Officer

OneGrand Central Place,

Suite4600

NewYork, New York 10165

(212)949-4319

(Name,Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

Copyto:

DavidAlan Miller

EricSchwartz

GraubardMiller

405Lexington Avenue 11^th Floor

NewYork, New York 10174

(212)818-8800

Approximatedate of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

Ifany of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under theSecurities Act of 1933, check the following box. ☒

Ifthis form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the followingbox and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐

Ifthis form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list theSecurities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Ifthis form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list theSecurities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

TheRegistrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until theRegistrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effectivein accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such dateas the Commission, acting pursuant to said Section 8(a), may determine.

Theinformation in this preliminary prospectus is not complete and may be changed. Neither we nor the selling securityholders may sell thesesecurities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectusis not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer orsale is not permitted.

LUCIDDIAGNOSTICS INC.

15,000,000Shares of Common Stock

Thisprospectus relates to the potential offer and sale from time to time by CF Principal Investments LLC (“Cantor” or the “Holder”)of up to 15,000,000 shares of our common stock, par value $0.001 per share (the “Common Stock”), that may be issued by usto the Holder pursuant to a common stock purchase agreement, dated as of March 28, 2022, by and between us and the Holder (the “PurchaseAgreement”) establishing a committed equity facility (the “Facility”).

Weare not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares of our common stockby the Holder. However, we may receive up to $50.0 million in aggregate gross proceeds from the Holder under the Purchase Agreement inconnection with sales of shares of Common Stock to the Holder pursuant to the Purchase Agreement after the date of this prospectus. Inconnection with the execution of the Purchase Agreement, the Company paid Cantor $1,000,000 as consideration for its irrevocable commitmentto purchase the shares upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement. In addition,pursuant to the Purchase Agreement, the Company agreed to reimburse Cantor for certain of its expenses.

TheHolder may offer, sell or distribute all or a portion of the shares registered hereby publicly or through private transactions at prevailingmarket prices or at negotiated prices. We will bear all costs, expenses and fees in connection with the registration of these shares,including with regard to compliance with state securities or “blue sky” laws. The timing and amount of any sale are withinthe sole discretion of the Holder. The Holder is an underwriter under the Securities Act of 1933, as amended (the “Securities Act”),and any profit on sale of the shares by it and any discounts, commissions or concessions received by it may be deemed to be underwritingdiscounts and commissions under the Securities Act. Although the Holder is obligated (subject to certain conditions) to purchase sharesof our Common Stock under the terms of the Purchase Agreement to extent we choose to sell such shares to them, there can be no assurancesthat the Holder will sell any or all of the shares purchased under the Purchase Agreement pursuant to this prospectus. The Holder willbear all commissions and discounts, if any, attributable to its sale of shares. We will also engage to act as a “qualified independentunderwriter” in this offering, whose fees and expenses will be borne by the Holder. See “Plan of Distribution (Conflictof Interest)” beginning on page 17.

Ourcommon stock is listed on the Global Market of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “LUCD.”On June 15, 2022, the last reported sale price of our Common Stock was $1.80 per share.

Weare an “emerging growth company” under federal securities laws and are subject to reduced public company reporting requirements.

Investingin our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading“Risk Factors” beginning on page 5 of this prospectus, in any amendment or supplements to this prospectus and in ourmost recent Annual Report on Form 10-K.

Neitherthe Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

Thedate of this prospectus is                , 2022.

TABLEOF CONTENTS

ABOUTTHIS PROSPECTUS

Thisprospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the “SEC”)using a “shelf” registration process. Under this shelf registration process, the Holder may, from time to time, sell thesecurities offered by them described in this prospectus. We will not receive any proceeds from the sale by the Holder of the securitiesoffered by them described in this prospectus. However, we may receive up to $50.0 million in aggregate gross proceeds from the Holderunder the Purchase Agreement in connection with sales of shares of our common stock to the Holder pursuant to the Purchase Agreementafter the date of this prospectus.

Neitherwe nor the Holder have authorized anyone to provide you with any information other than that provided in this prospectus, as well asany information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the Holder canprovide any assurance as to the reliability of any other information that others may give you. Neither we nor the Holder are making anoffer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus,any applicable prospectus supplement or any documents incorporated by reference is accurate as of any date other than the date of theapplicable document. Since the respective dates of this prospectus and the documents incorporated by reference into this prospectus,our business, financial condition, results of operations and prospects may have changed.

Wemay also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update orchange information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effectiveamendment to the registration statement together with the additional information to which we refer you in the sections of this prospectusentitled “Where You Can Find More Information.”

Unlessthe context indicates otherwise, references in this prospectus to the “Company,” “Lucid,” “we,” “us,”“our” and similar terms refer to Lucid Diagnostics Inc., a Delaware corporation, and its subsidiaries.

MARKETAND INDUSTRY DATA

Weobtained the market, industry and competitive position data used throughout this prospectus from our own internal estimates and research,as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly availableinformation in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from publicly availableinformation released by industry analysts and third-party sources, our internal research and our industry experience, and are based onassumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases,we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of thistype of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the samesources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market andcompetitive position data included in this prospectus are reliable and based on reasonable assumptions, such data involve risks and uncertaintiesand are subject to change based on various factors, including those discussed in the section titled “Risk Factors.”These and other factors could cause results to differ materially from those expressed in the estimates made by the independent partiesor by us.

TRADEMARKS

Wehave proprietary rights to trademarks used in this prospectus, including Lucid Diagnostics™, EsoGuard®, EsoCheck® and Collect+Protect™.Solely for our convenience, trademarks and trade names referred to in this prospectus may appear without the “®” or “™”symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent possible underapplicable law, our rights or the rights to these trademarks and trade names. We do not intend our use or display of other companies’trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.Each trademark, trade name, or service mark of any other company appearing in this prospectus is the property of its respective holder.

CAUTIONARYNOTE REGARDING FORWARD-LOOKING STATEMENTS

Thisprospectus contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21Eof the Exchange Act. The statements contained in this prospectus supplement and in the documents incorporated by reference in this prospectussupplement that are not purely historical are forward-looking statements. Forward-looking statements include, but are not limited to,statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future, such as:

Inaddition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, includingany underlying assumptions, are forward-looking statements. The words “anticipates,” “believes,” “continues,”“could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,”“possible,” “potential,” “predicts,” “projects,” “should,” “would”and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is notforward-looking.

Theforward-looking statements contained in this prospectus and in the documents incorporated by reference in this prospectus are based oncurrent expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that futuredevelopments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (someof which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from thoseexpressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factorsincorporated by reference or described in “Risk Factors,” as well as the following:

Shouldone or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary inmaterial respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise anyforward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicablesecurities laws.

RISKFACTORS

Ourbusiness involves a high degree of risk. You should carefully consider the risks described below, together with the other informationcontained or incorporated by reference in this prospectus, including the information in Item 1A, “Risk Factors,” in our annualreport on Form 10-K, which is incorporated herein by reference and any amendment or update thereto reflected in subsequent filings with the SEC and incorporated by reference inthis prospectus. We cannot assure you that any of the events discussed in the risk factorsbelow will not occur. These risks could have a material and adverse impact on our business, prospects, results of operations, financialcondition and cash flows. If any such events were to happen, the trading price of our common stock could decline, and you could loseall or part of your investment.

RisksRelated to the Committed Equity Financing

Itis not possible to predict the actual number of shares of Common Stock, if any, we will sell under the Purchase Agreement to Cantor,or the actual gross proceeds resulting from those sales.

OnMarch 28, 2022, we entered into the Purchase Agreement with Cantor, pursuant to which Cantor has committed to purchase up to $50.0 millionshares of our Common Stock, subject to certain limitations and conditions set forth in the Purchase Agreement. The shares of Common Stockthat may be issued under the Purchase Agreement may be sold by us to Cantor at our discretion from time to time until the first day ofthe month next following the 36-month period commencing on the date of this prospectus.

Wegenerally have the right to control the timing and amount of any sales of shares to Cantor under the Purchase Agreement. Sales of shares,if any, to Cantor under the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimatelydecide to sell to Cantor all, some or none of the shares of Common Stock that may be available for us to sell to Cantor pursuant to thePurchase Agreement.

Becausethe purchase price per shares to be paid by Cantor for the shares of Common Stock that we may elect to sell to Cantor under the PurchaseAgreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to Cantor pursuantto the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales,the number of shares of Common Stock that we will sell to Cantor under the Purchase Agreement, the purchase price per share that Cantorwill pay for shares of Common Stock purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receivefrom those purchases by Cantor under the Purchase Agreement.

Althoughthe Purchase Agreement provides that we may, in our discretion, from time to time after the date of this prospectus and during the termof the Purchase Agreement, direct Cantor to purchase shares of our Common Stock from us in one or more purchases under the Purchase Agreement,for a maximum aggregate purchase price of up to $50.0 million, only 15,000,000 shares of Common Stock are being registered for resaleunder the registration statement that includes this prospectus. However, because the market prices of our Common Stock may fluctuatefrom time to time after the date of this prospectus and, as a result, the actual purchase prices to be paid by Cantor for shares of ourCommon Stock that we direct it to purchase under the Purchase Agreement, if any, also may fluctuate significantly based on the marketprice of our Common Stock.

Accordingly,if we decide to issue and sell to Cantor under the Purchase Agreement more than the 15,000,000 shares being registered for resale underthis registration statement in order to receive additional proceeds (which we may elect to do, at our sole discretion, up to aggregategross proceeds of $50.0 million), we must first file with the SEC one or more additional registration statements to register the resaleunder the Securities Act by Cantor of any such additional shares of Common Stock we wish to sell from time to time under the PurchaseAgreement, which the SEC must declare effective before we may elect to sell any such additional shares to Cantor under the Purchase Agreement.Any issuance and sale by us under the Purchase Agreement of a substantial amount of shares of Common Stock in addition to the 15,000,000shares being registered for resale by Cantor under this prospectus could cause additional substantial dilution to our shareholders. Thenumber of shares of Common Stock ultimately offered for sale by Cantor is dependent upon the number of shares, if any, we ultimatelyelect to sell to Cantor under the Purchase Agreement. However, even if we elect to sell shares of Common Stock to Cantor pursuant tothe Purchase Agreement, Cantor may resell all, some or none of such shares at any time or from time to time in its sole discretion andat different prices.

Asubstantial number of shares of our Common Stock may be sold in this offering, which could cause the price of our common stock to decline.

Thesale of shares to be issued in this offering in the public market, or any future sales of a substantial number of shares of our CommonStock in the public market, or the perception that such sales may occur, could adversely affect the price of our Common Stock on theNasdaq Global Market. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability ofthose shares of common stock for sale will have on the market price of our Common Stock.

Investorswho buy shares of Common Stock from the Holder at different times will likely pay different prices.

Pursuantto the Purchase Agreement, we will have discretion, to vary the timing, price and number of shares sold to Cantor. If and when we electto sell shares of Common Stock to Cantor pursuant to the Purchase Agreement, after Cantor has acquired such shares, Cantor may resellall, some or none of such shares at any time or from time to time in its sole discretion and at different prices. As a result, investorswho purchase shares from Cantor in this offering at different times will likely pay different prices for those shares, and so may experiencedifferent levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors mayexperience a decline in the value of the shares they purchase from Cantor in this offering as a result of future sales made by us toCantor at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial numberof shares to Cantor under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existenceof our arrangement with Cantor may make it more difficult for us to sell equity or equity-related securities in the future at a timeand at a price that we might otherwise wish to effect such sales.

Wewill require additional capital funding, the receipt of which may impair the value of our common stock.

Ourfuture capital requirements depend on many factors, including our research, development, and sales and marketing activities. We intendto continue to make investments to support our business growth. Because we have not generated any revenue or cash flow to date, we mayrequire additional funds to:

Ifwe do not have, or are not able to obtain, sufficient funds, we may have to delay product development initiatives or license to thirdparties the rights to commercialize products or technologies we would otherwise seek to market. We also may have to reduce marketing,customer support or other resources devoted to our products.

Weexpect to need to raise additional capital beyond the Facility through public or private equity or debt offerings or through arrangementswith strategic partners or other sources in order to continue to develop and commercialize our products and product candidates. Therecan be no assurance that such additional capital will be available when needed or on terms satisfactory to us, if at all. To the extentwe raise additional capital by issuing equity securities, our stockholders may experience substantial dilution and the new equity securitiesmay have greater rights, preferences or privileges than our existing common stock.

Wedo not expect to pay any dividends in the foreseeable future.

Wehave not paid any cash dividends on our shares of common stock to date. The payment of cash dividends on our common stock in the futurewill be dependent upon our revenues and earnings, if any, capital requirements and general financial condition and will be within thediscretion of our board of directors. It is the present intention of our board of directors to retain all earnings, if any, for use inour business operations and, accordingly, our board of directors does not anticipate declaring any dividends on our common stock in theforeseeable future. As a result, any gain you will realize on our common stock will result solely from the appreciation of such shares.

Ourstock price may be volatile, and purchasers of our securities could incur substantial losses.

Ourstock price is likely to be volatile. The stock market in general, and the market for life science companies, and medical device companiesin particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.As a result of this volatility, investors may experience losses on their investment in our common stock.

Forexample, on May 31, 2022, the price of our common stock closed at $2.10 per share. In the last six months, between December 1, 2021 andMay 31, 2022, the intra-day sales price of our common stock fluctuated between a reported low sale price of $1.79 and a reported highsales price of $7.98. We may incur rapid and substantial increases or decreases in our stock price in the foreseeable future that donot coincide in timing with the disclosure of news or developments by us.

Themarket price for our common stock may be influenced by many factors, including the following:

Thesebroad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Inthe past, following periods of volatility in the market, securities class action litigation has often been instituted against companies.Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources,which could materially and adversely affect our business, financial condition, results of operations and growth prospects.

Wemay use proceeds from sales of shares of our Common Stock made pursuant to the Purchase Agreement in ways with which you may not agreeor in ways which may not yield a significant return.

Wewill have broad discretion over the use of proceeds from sales of shares of our Common Stock made pursuant to the Purchase Agreement,including for any of the purposes described in the section entitled “Use of Proceeds,” and you will not have the opportunity,as part of your investment decision, to assess whether the proceeds are being used appropriately. However, we have not determined thespecific allocation of any net proceeds among these potential uses, and the ultimate use of the net proceeds may vary from the currentlyintended uses. The net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value ofour Common Stock.

THECOMMITTED EQUITY FINANCING

OnMarch 28, 2022, we entered into the Purchase Agreement with Cantor establishing a committed equity facility (the “Facility”).Upon the initial satisfaction of the conditions to Cantor’s obligation to purchase Shares set forth in the Purchase Agreement (the“Commencement Date”), including that the registration statement of which this prospectus forms a part is declared effectiveby the SEC and a final prospectus relating thereto is filed with the SEC, we have the right from time to time at our option to directCantor to purchase shares of our Common Stock, up to a maximum aggregate purchase price of $50.0 million.

Salesof shares of our Common Stock to Cantor under the Purchase Agreement, and the timing of any sales, will be determined by us from timeto time in our sole discretion and will depend on a variety of factors, including, among other things, market conditions, the tradingprice of our Common Stock and determinations by us regarding the use of proceeds from any sale of such shares. The net proceeds fromany sales under the Facility will depend on the frequency with, and prices at, which the shares of Common Stock are sold to Cantor.

Inconnection with the execution of the Purchase Agreement, the Company paid Cantor $1,000,000 as consideration for its irrevocable commitmentto purchase the Shares upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement. In addition,pursuant to the Purchase Agreement, the Company agreed to reimburse Cantor for certain of its expenses. Unless earlier terminated, thePurchase Agreement will remain in effect until the first day of the month next following the 36-month period commencing on the date ofthis prospectus.

Underapplicable Nasdaq rules, in no event may we issue to Cantor more than 19.99% of the total number of shares of our Common Stock that wereoutstanding immediately prior to the execution of the Purchase Agreement, unless we obtain prior shareholder approval (the “ExchangeCap”). We intend to submit a proposal to approve the issuance of shares under the Facility to our stockholders at our annual meetingof stockholders scheduled to be held on June 21, 2022. If the proposal is approved, the Exchange Cap will cease to apply.

Inaddition, Cantor is not obligated to buy any shares of Common Stock under the Purchase Agreement if such shares, when aggregated withall other shares of Common Stock then beneficially owned by Cantor and its affiliates (as calculated pursuant to Section 13(d) of theExchange Act and Rule 13d-3 promulgated thereunder), would result in Cantor beneficially owning shares in excess of 4.99% of our outstandingshares of Common Stock (the “Beneficial Ownership Cap”).

Wealso entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Cantor, pursuant to which wefiled the registration statement of which this prospectus forms a part.

ThePurchase Agreement contains customary registration rights, representations, warranties, conditions and indemnification obligations byeach party. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of the PurchaseAgreement and as of specific dates, were solely for the benefit of the parties to such agreements and are subject to certain importantlimitations.

VWAPPurchase of Shares Under the Purchase Agreement

Fromand after the Commencement Date, subject to certain conditions, we will have the right, but not the obligation, from time to time atour sole discretion, until the first day of the month next following the 36-month period from the Commencement Date, to direct Cantorto purchase up to a specified maximum amount of shares of our Common Stock (each such purchase, a “VWAP Purchase”) by deliveringwritten notice to Cantor (such notice, a “VWAP Purchase Notice”) on any trading day (the “VWAP Purchase Date”),so long as all shares of Common Stock subject to all prior VWAP Purchases by Cantor have previously been delivered to Cantor.

Themaximum number of shares of Common Stock that Cantor is required to purchase in any single VWAP Purchase under the Purchase Agreementis equal to the least of: (i) a number of shares of Common Stock which, when aggregated with all other shares then beneficially ownedby Cantor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), wouldresult in Cantor beneficially owning shares of Common Stock equal to (but not exceeding) the Beneficial Ownership Cap; (ii) a numberof shares of Common Stock equal to 20% of the total number (or volume) of shares of Common Stock traded on Nasdaq during normal tradinghours on the applicable VWAP Purchase Date; and (iii) the Company’s good faith estimate of the number of number of shares thatCantor will have the obligation to buy pursuant to the VWAP Purchase Notice.

Thepurchase price purchase price per share to be purchased by Cantor in such VWAP Purchase on such VWAP Purchase Date equal to 96.0% ofthe VWAP over normal trading hours on such VWAP Purchase Date for such VWAP Purchase (the “VWAP Purchase Price”). Notwithstandinganything in this Agreement to the contrary, on any trading day on which we deliver, and Cantor accepts, a VWAP Purchase Notice for apercentage in excess of 20%, the VWAP Purchase Price shall be calculated using the lower of (i) the VWAP over normal trading hours onsuch VWAP Purchase Date; and (ii) the lowest Sale Price in any block sold on such Trading Day following the delivery and acceptance ofsuch VWAP Purchase Notice for a percentage in excess of 20%. “VWAP” is defined as, for the Common Stock for a specified period,the dollar volume-weighted average price for the Common Stock on the Principal Market, for such period, as reported by Bloomberg throughits “AQR” function. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination,recapitalization or other similar transaction during such period.

Ator prior to 5:30 p.m., New York City time, on the applicable VWAP Purchase Date, Cantor will provide us with a written confirmation forsuch VWAP Purchase setting forth the applicable VWAP Purchase Price per share to be paid by Cantor and the total aggregate VWAP PurchasePrice to be paid by Cantor for the total number of shares of our Common Stock purchased by Cantor in such VWAP Purchase.

Thepayment for, against delivery of, shares of Common Stock purchased by Cantor in a VWAP Purchase under the Purchase Agreement is requiredto be fully settled by 5:00 p.m., New York City time, on the second trading day immediately following the applicable date of such VWAPPurchase Date, as set forth in the Purchase Agreement.

ConditionsPrecedent to Commencement and Each VWAP Purchase

Cantor’sobligation to accept VWAP Purchase Notices that are timely delivered by us under the Purchase Agreement and to purchase shares of ourCommon Stock in VWAP Purchases under the Purchase Agreement, are subject to the satisfaction, at the official open of trading on theVWAP Purchase Date, of the conditions precedent thereto set forth in the Purchase Agreement, which conditions include, among others,the following:

Terminationof the Purchase Agreement

Unlessearlier terminated as provided in the Purchase Agreement, the Purchase Agreement will terminate automatically on the earliest to occurof:

Pursuantto the Purchase Agreement, we may terminate this Agreement after the Commencement Date effective upon three trading days’ priorwritten notice to Cantor in accordance with the Purchase Agreement.

ThisAgreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual writtenconsent unless otherwise provided in such written consent.

Cantorshall have the right to terminate this Agreement effective upon three trading days’ prior written notice to us, which notice shallbe made in accordance with the Purchase Agreement, if: (a) any condition, occurrence, state of facts or event constituting a MaterialAdverse Effect has occurred and is continuing; (b) a Fundamental Transaction (as defined in the Purchase Agreement) shall have occurred;(c) we are in breach or default in any material respect of any of its covenants and agreements in the Registration Rights Agreement,and, if such breach or default is capable of being cured, such breach or default is not cured within 15 trading days after notice ofsuch breach or default is delivered to us; (d) while the registration statement of which this prospectus forms a part is required tobe maintained effective pursuant to the Registration Rights Agreement and Cantor holds any securities required to be registered pursuantto the Registration Rights Agreement, the effectiveness of the registration statement lapses for any reason (including, without limitation,the issuance of a stop order by the SEC) or the registration statement or this prospectus otherwise becomes unavailable to Cantor forthe resale of all of the securities required to be registered, and such lapse or unavailability continues for a period of 45 consecutivetrading days or for more than an aggregate of 90 trading days in any 365-day period, other than due to acts of Cantor; (e) trading inthe Common Stock on Nasdaq shall have been suspended and such suspension continues for a period of five consecutive trading days; or(f) we are in material breach or default of any of our covenants and agreements contained in the Purchase Agreement, and, if such breachor default is capable of being cured, such breach or default is not cured within 15 trading days after notice of such breach or defaultis delivered to us.

NoShort-Selling or Hedging by Cantor

Subjectto the terms of the Purchase Agreement, Cantor hasagreed that, during the term of the Purchase Agreement, neither it nor any entity managed or controlled by it,will engage in or effect, directly or indirectly, engage in any “short sale” (as such term is defined in Rule 200 of RegulationSHO of the Exchange Act) of the Common Stock or hedging transaction, which establishes a net short position with respect to the CommonStock.

Prohibitionon Similar Transactions

Wehave agreed not effect or enter into an agreement to effect an “equity line of credit,” “at the market offering,”“equity distribution program” or any similar transaction whereby we may issue or sell Common Stock or Common Stock equivalentsat a future determined price, other than in connection with certain exempt issuances.

Effectof Sales of Our Shares under the Purchase Agreement on Our Shareholders

Theshares of Common Stock being registered for resale in this offering may be issued and sold by us to Cantor from time to time at our discretionover a period until the first day of the month next following the 36-month anniversary of the date of this prospectus, unless the PurchaseAgreement is earlier terminated as described above. The resale by Cantor of a significant number of shares registered for resale in thisoffering at any given time, or the perception that these sales may occur, could cause the market price of our Common Stock to declineand to be highly volatile. Sales of shares of our Common Stock, if any, to Cantor under the Purchase Agreement will be determined byus in our sole discretion and will depend upon market conditions and other factors. We may ultimately decide to sell to Cantor all, someor none of the shares of our Common Stock that may be available for us to sell to Cantor pursuant to the Purchase Agreement. If and whenwe elect to sell shares of our Common Stock to Cantor pursuant to the Purchase Agreement, Cantor may resell all, some or none of suchshares at any time or from time to time in its discretion and at different prices. As a result, investors who purchase shares from Cantorin this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilutionand in some cases substantial dilution and different outcomes in their investment results. See “Risk Factors—Risks Relatedto the Committed Equity Financing—Investors who buy shares of our Common Stock from Cantor at different times will likely pay differentprices.”

Investorsmay experience a decline in the value of the shares they purchase from Cantor in this offering as a result of future sales made by usto Cantor at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantialnumber of shares of our Common Stock to Cantor under the Purchase Agreement, or if investors expect that we will do so, the actual salesof shares or the mere existence of our arrangement with Cantor may make it more difficult for us to sell equity or equity-related securitiesin the future at a time and at a price that we might otherwise wish to effect such sales.

Becausethe purchase price per share to be paid by Cantor for the shares of our Common Stock that we may elect to sell to Cantor under the PurchaseAgreement, if any, will fluctuate based on the market prices of our Common Stock during the applicable period for each VWAP Purchasemade pursuant to the Purchase Agreement, if any, as of the date of this prospectus it is not possible for us to predict the number ofshares that we will sell to Cantor under the Purchase Agreement, the actual purchase price per share to be paid by Cantor for those shares,or the actual gross proceeds to be raised by us from those sales, if any. As of May 31, 2022, 38,138,036 shares of our CommonStock are issued and outstanding. Although the Purchase Agreement provides that we may sell up to an aggregate gross purchase price of$50.0 million in shares of our Common Stock to Cantor, only 15,000,000 shares are being registered for resale under the registrationstatement that includes this prospectus.

Ifall of the 15,000,000 shares of our Common Stock offered for resale by Cantor under this prospectus were issued and outstanding as ofMay 31, 2022, such shares would represent approximately 28.2% of the total number of our Common Stock outstanding.

Ifwe decide to issue and sell to Cantor under the Purchase Agreement more than the 15,000,000 shares of our Common Stock that are beingoffered for resale under this prospectus, which we may elect to do, at our sole discretion, up to aggregate gross proceeds under theFacility of $50.0 million, in order to receive additional proceeds we must first file with the SEC one or more additional registrationstatements to register the resale under the Securities Act by Cantor of any such additional shares we wish to sell from time to timeunder the Purchase Agreement, which the SEC must declare effective, in each case before we may elect to sell any such additional sharesto Cantor under the Purchase Agreement. The number of shares of our Common Stock ultimately offered for sale by Cantor for resale underthis prospectus in order to receive or under any future prospectus is dependent upon the number of shares, if any, we ultimately sellto Cantor under the Purchase Agreement. Further, if and when we elect to sell shares of our Common Stock to Cantor pursuant to the PurchaseAgreement, after Cantor has acquired such shares, Cantor may resell all, some or none of such shares at any time or from time to timein its discretion and at different prices.

Theissuance of our shares of our Common Stock to Cantor pursuant to the Purchase Agreement will not affect the rights or privileges of ourexisting shareholders, except that the economic and voting interests of each of our existing shareholders will be diluted. Although thenumber of shares that our existing shareholders own will not decrease, the shares owned by our existing shareholders will represent asmaller percentage of our total outstanding Common Stock after any such issuance.

Thefollowing table sets forth information at varying purchase prices assuming we sell to Cantor under the Purchase Agreement the lesserof (i) the maximum number of shares of our Common Stock offered by this prospectus and (ii) the maximum number of shares of our CommonStock that we may sell to Cantor that results in the sale of shares with an aggregate purchase price of $50.0 million:

USEOF PROCEEDS

Anysales of shares of Common Stock by the Holder pursuant to this prospectus will be solely for the Holder’s account. The Companywill not receive any proceeds from any such sales. However, we may receive up to $50.0 million in aggregate gross proceeds from the Holderunder the Purchase Agreement in connection with sales of shares of our Common Stock to the Holder pursuant to the Purchase Agreementafter the date of this prospectus. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, andprices at, which the Shares are sold to Cantor. The Company expects to use the proceeds from any sales under the Purchase Agreement forworking capital and general corporate purposes. See “Plan of Distribution (Conflict of Interest)” and “TheCommitted Equity Financing” elsewhere in this prospectus for more information.

Weintend to use any proceeds from the Facility for working capital and general corporate purposes. We will have broad discretion in theway we use these proceeds. See “Risk Factors—Risks Related to the Committed Equity Financing—We may use proceedsfrom sales of shares of our Common Stock made pursuant to the Purchase Agreement in ways with which you may not agree or in ways whichmay not yield a significant return.”

TheHolder will pay any underwriting fees, discounts and selling commissions incurred by such Holder in connection with any sale of theirshares. We will also engage             to act as a “qualified independent underwriter” in this offering, whose fees and expenseswill be borne by the Holder. The Company will bear all other costs, fees and expenses incurred in effecting the registration of theshares covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees andexpenses of counsel and independent registered public accountants.

MARKETINFORMATION FOR COMMON STOCK AND DIVIDEND POLICY

MarketInformation

TheCommon Stock is currently listed on the Nasdaq Global Market under the symbol “LUCD.”

Holders

Asof May 31, 2022, there were 15 holders of record of our Common Stock. We believe our Common Stock is held by over 4,200 beneficial holders.

DividendPolicy

Wehave not declared or paid any dividends on our Common Stock to date. We anticipate that we will retain all of our future earnings, ifany, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. Anydecision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on,among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors thatour board of directors may deem relevant.

SELLINGHOLDER

Thisprospectus relates to the possible offer and resale from time to time by the Holder of up to 15,000,000 shares of our Common Stock thatmay be issued by us to the Holder pursuant to the Purchase Agreement. For additional information regarding the issuance of the sharesto be offered by the Holder included in this prospectus, see “Committed Equity Financing” above. We are registeringthe shares included in this prospectus pursuant to the provisions of the Registration Rights Agreement in order to permit the Holderto offer the shares for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and as set forthin the section titled “Plan of Distribution (Conflict of Interest)” in this prospectus, the Holder has not had anymaterial relationship with us or any of our affiliates within the past three years. All of the data in the following table is as of May31, 2022.

Thefollowing tables was prepared based on information provided to us by the Holder. It sets forth the name and address of the Holder, theaggregate number of shares of our Common Stock that the Holder may offer pursuant to this prospectus, and the beneficial ownership ofthe Holder both before and after giving effect to the offering, assuming we sell to the Holder all of the 15,000,000 shares covered bythis prospectus. We have calculated percentage ownership based on 38,138,036 shares of our Common Stock outstanding as of May 31, 2022.

Wecannot advise you as to whether the Holder will in fact sell any or all of the securities set forth in the table below or how long theHolder will hold any shares before selling them. In addition, subject to compliance with applicable securities laws, the Holder may sell,transfer or otherwise dispose of, at any time and from time to time, such securities in transactions exempt from the registration requirementsof the Securities Act after the date of this prospectus. Because the purchase price of the shares that may be issued under the PurchaseAgreement is determined on each purchase date with respect to each purchase, the number of shares that we may actually sell to the Holderunder the Purchase Agreement may be fewer than or more than the number of shares being offered by this prospectus. For purposes of thebelow table, unless otherwise indicated below, we have assumed that the Holder will have sold all of the securities covered by this prospectusupon the completion of the offering.

PLANOF DISTRIBUTION (CONFLICT OF INTEREST)

Weare registering the resale by the Holder of 15,000,000 shares of our Common Stock.

Wewill not receive any of the proceeds from the sale of the securities by the Holder. However, we may receive up to $50.0 million in aggregategross proceeds from the Holder under the Purchase Agreement in connection with sales of our shares of our Common Stock to the Holderpursuant to the Purchase Agreement after the date of this prospectus. The aggregate proceeds to the Holder will be the purchase priceof the securities less any discounts and commissions borne by the Holder.

Theshares beneficially owned by the Holder covered by this prospectus may be offered and sold from time to time by the Holder. The term“Holder” includes donees, pledgees, transferees or other successors in interest selling securities received after the dateof this prospectus from a Holder as a gift, pledge, partnership distribution or other transfer. The Holder will act independently ofus in making decisions with respect to the timing, manner and size of each sale by the Holder. Such sales may be made on one or moreexchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the thencurrent market price or in negotiated transactions. The Holder may sell its shares of our Common Stock by one or more of, or a combinationof, the following methods:

Inaddition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.

Wecannot currently determine the price or prices at which shares of our Common Stock may be sold by the Holder under this prospectus.

TheHolder is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act. The Holder has informed us thatit intends to use one or more registered broker-dealers (one of which is an affiliate of the Holder) to effectuate all sales, if any,of shares of our Common Stock that it may acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and atterms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriterwithin the meaning of Section 2(a)(11) of the Securities Act. The Holder has informed us that each such broker-dealer (excluding anybroker-dealer that is an affiliate of the Holder), may receive commissions from the Holder for executing such sales for the Holder and,if so, such commissions will not exceed customary brokerage commissions.

Asconsideration for its irrevocable commitment to, at our request, purchase shares of our Common Stock under the Purchase Agreement, weissued the Commitment Fee Shares to Cantor upon execution of the Purchase Agreement. In addition, pursuant to the Purchase Agreementwe have agreed to pay the Usage Fees to the Holder as such fees become payable under the terms of the Purchase Agreement. Further, wealso have agreed to reimburse Cantor up to $75,000 for the fees and disbursements of its counsel in connection with the transactionscontemplated by the Purchase Agreement and up to $25,000 per fiscal quarter thereafter in connection with the Holder’s ongoingdue diligence review.

Wealso have agreed to indemnify the Holder and certain other persons against certain liabilities in connection with the offering of sharesoffered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts requiredto be paid in respect of such liabilities. The Holder has agreed to indemnify us against liabilities under the Securities Act that mayarise from certain written information furnished to us by the Holder specifically for use in this prospectus or, if such indemnity isunavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arisingunder the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinionof the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.

Tothe extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. Inconnection with distributions of the shares or otherwise, the Holder may enter into hedging transactions with broker-dealers or otherfinancial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short salesof shares of our Common Stock in the course of hedging transactions, and broker-dealers or other financial institutions may engage inshort sales of shares of our Common Stock in the course of hedging the positions they assume with Holder. The Holder may also sell sharesof our Common Stock short and redeliver the shares to close out such short positions, subject to restrictions described above under “TheCommitted Equity Financing—No Short-Selling or Hedging by Cantor.” The Holder may also enter into option or other transactionswith broker-dealers or other financial institutions which require the delivery to such broker- dealer or other financial institutionof shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus(as supplemented or amended to reflect such transaction). The Holder may also pledge shares to a broker-dealer or other financial institution,and, upon a default, such broker-dealer or other financial institution may effect sales of the pledged shares pursuant to this prospectus(as supplemented or amended to reflect such transaction).

TheHolder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third partiesin privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the thirdparties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.If so, the third party may use securities pledged by any Holder or borrowed from the Holder or others to settle those sales or to closeout any related open borrowings of stock, and may use securities received from the Holder in settlement of those derivatives to closeout any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified inthe applicable prospectus supplement (or a post-effective amendment). In addition, the Holder may otherwise loan or pledge securitiesto a financial institution or other third party that in turn may sell the securities short using this prospectus. Such financial institutionor other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offeringof other securities.

Ineffecting sales, broker-dealers or agents engaged by the Holder may arrange for other broker-dealers to participate. Broker-dealers oragents may receive commissions, discounts or concessions from the Holder in amounts to be negotiated immediately prior to the sale.

Inorder to comply with the securities laws of certain states, if applicable, the shares must be sold in such jurisdictions only throughregistered or licensed brokers or dealers. In addition, in certain states the shares may not be sold unless they have been registeredor qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and iscomplied with.

Wehave advised the Holder that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the marketand to the activities of the Holder and its affiliates. In addition, we will make copies of this prospectus available to the Holder forthe purpose of satisfying the prospectus delivery requirements of the Securities Act. The Holder may indemnify any broker-dealer thatparticipates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the SecuritiesAct.

Atthe time a particular offer of shares is made, if required, a prospectus supplement will be distributed that will set forth the numberof shares being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paidby any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowedor reallowed or paid to any dealer, and the proposed selling price to the public.

Exceptas described below, we know of no existing arrangements between the Holder or any other shareholder, broker, dealer, underwriter or agentrelating to the sale or distribution of the shares offered by this prospectus.

Conflict of Interest

TheHolder is an affiliate of CF&CO, a FINRA member which will act as an executing broker for the sale of shares of our Common Stockto the public in this offering. Because the Holder will receive all the net proceeds from sales of shares made to the public throughCF&CO, CF&CO is deemed to have a “conflict of interest” within the meaning of FINRA Rule 5121. Consequently thisoffering will be conducted in compliance with the provisions of FINRA Rule 5121, which requires that a “qualified independent underwriter,”as defined by FINRA participate in the preparation of the registration statement and exercise the usual standard of “due diligence”with respect to such document. We have engaged             , to be the qualifiedindependent underwriter and participate in the preparation of the registration statement and exercise the usual standards of “duediligence” in respect thereto. Cantor has agreed to pay             afee of $             upon the completion of this offering in considerationfor its services and expenses as the qualified independent underwriter.             willreceive no other compensation. In accordance with Rule 5121 CF&CO is not permitted to sell shares in this offering to an accountover which it exercises discretionary authority without the prior specific written approval of the account holder.

LEGALMATTERS

GraubardMiller have passed upon the validity of the Common Stock offered by this prospectus and certain other legal matters related to this prospectus.

EXPERTS

Theconsolidated financial statements of Lucid Diagnostics, Inc. as of December 31, 2021 and 2020, and for each of the two years in the periodended December 31, 2021, incorporated by reference in this Prospectus and Registration Statement from our Annual Report of Form 10-Kfor the year ended December 31, 2021, have been audited by Marcum LLP, independent registered public accounting firm, as set forth intheir report thereon, included therein, and incorporated by reference in reliance upon such report given on the authority of such firmas experts in accounting and auditing.

WHEREYOU CAN FIND MORE INFORMATION

Wehave filed a registration statement on Form S-1, including exhibits, under the Securities Act of 1933, as amended, with respect to thesecurities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement.For further information pertaining to us and our securities, you should refer to the registration statement and our exhibits.

Inaddition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are availableto the public on a website maintained by the SEC located at http://www.sec.gov. We also maintain a website at http://www.luciddx.com.Through our website at https://ir.luciddx.com/sec-filings, we make available, free of charge, annual, quarterly and current reports,proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, theSEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus.

INCORPORATIONOF DOCUMENTS BY REFERENCE

TheSEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information toyou by referring you to those documents. Any statement contained in a document incorporated by reference herein shall be deemed to bemodified or superseded for purposes of this prospectus to the extent that a statement contained herein modifies or supersedes such statement.Any information that we file after the date of this prospectus with the SEC will automatically update and supersede the information containedin this prospectus or in a document previously incorporated by reference herein. Any statement so modified or superseded shall not bedeemed, except as so modified or superseded, to constitute a part of this prospectus.

Thisprospectus incorporates by reference (i) the documents listed below, (ii) any future filings we make with the SEC under Sections 13(a),13(c), 14 or 15(d) of the Exchange Act, after the date of the initial filing of the registration statement of which this prospectus isa part and prior to effectiveness of such registration statement, and (iii) any future filings we make with the SEC under Sections 13(a),13(c), 14 or 15(d) of the Exchange Act after effectiveness of such registration statement until all of the securities are sold or wederegister all securities then remaining unsold:

Notwithstandingthe foregoing, any documents or information deemed to have been furnished and not filed in accordance with SEC rules shall not be deemedincorporated by reference into this prospectus.

Wewill furnish, without charge, upon written or oral request, to each person to whom this prospectus is delivered, a copy of any or allof the documents incorporated by reference (without such documents’ exhibits). Requests should be directed to, Lucid DiagnosticsInc., One Grand Central Place, Suite 4600, New York, NY 10165, telephone number (212) 949-4319, Attention: Secretary.

Wemaintain an Internet site at http://www.luciddx.com, where the documents that are incorporated by reference may be found. See “WhereYou Can Find More Information” above. Our website and the information contained on that site, or connected to that site, arenot incorporated into this prospectus or the registration statement of which this prospectus is a part.

15,000,000Shares of Common Stock

LUCIDDIAGNOSTICS INC.

PROSPECTUS

               ,2022

PARTII
INFORMATION NOT REQUIRED IN PROSPECTUS

Thefollowing is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securitiesbeing registered hereby.

Wewill bear all costs, expenses and fees in connection with the registration of the securities, including with regard to compliance withstate securities or “blue sky” laws. The Holder, however, will bear all commissions and other amounts, if any, attributableto its sale of the securities. All amounts are estimates except the SEC registration fee and the FINRA fee.

Section145 of the Delaware General Corporation Law, relating to indemnification our officers, directors, employees and agents, provides as follows:

“Section145. Indemnification of officers, directors, employees and agents; insurance.

“(a)A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pendingor completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in theright of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation,or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership,joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlementactually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith andin a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to anycriminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action,suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself,create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposedto the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe thatthe person’s conduct was unlawful.

“(b)A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pendingor completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the personis or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (includingattorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action orsuit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests ofthe corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shallhave been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which suchaction or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstancesof the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other courtshall deem proper.

“(c)To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defenseof any action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue or mattertherein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by suchperson in connection therewith.

“(d)Any indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only asauthorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agentis proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) ofthis section. Such determination shall be made, with respect to a person who is a director or officer at the time of such determination,(1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (2)by a committee of such directors designated by majority vote of such directors, even though less than a quorum, or (3) if there are nosuch directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4) by the stockholders.

“(e)Expenses (including attorneys’ fees) incurred by an officer or director in defending any civil, criminal, administrative or investigativeaction, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding uponreceipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined thatsuch person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys’fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any,as the corporation deems appropriate.

“(f)The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall notbe deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw,agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity andas to action in another capacity while holding such office.

“(g)A corporation shall have power to purchase and maintain insurance on behalf of any person who is or was director, officer, employee oragent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of anothercorporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred bysuch person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have thepower to indemnify such person against such liability under this section.

“(h)For purposes of this section, references to “the corporation” shall include, in addition to the resulting corporation, anyconstituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existencehad continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person whois or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituentcorporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,shall stand in the same position under this section with respect to the resulting or surviving corporation as such person would havewith respect to such constituent corporation if its separate existence had continued.

“(i)For purposes of this section, references to “other enterprises” shall include employee benefit plans; references to “fines”shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to “serving at therequest of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposesduties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participantsor beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participantsand beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of thecorporation” as referred to in this section.

“(j)The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided whenauthorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefitof the heirs, executors and administrators of such a person.

“(k)The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnificationbrought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Court ofChancery may summarily determine a corporation’s obligation to advance expenses (including attorneys’ fees).”

Ouramended and restated certificate of incorporation provide that all persons whom we have the power to indemnify under Delaware law, includingour directors and officers, shall be entitled to be indemnified by us to the fullest extent permitted by Delaware law. Paragraph B ofArticle Seventh of our certificate of incorporation provides as follows:

“TheCorporation, to the full extent permitted by Section 145 of the GCL, as amended from time to time, shall indemnify all persons whom itmay indemnify pursuant thereto. Expenses (including attorneys’ fees) incurred by an officer or director in defending any civil,criminal, administrative, or investigative action, suit or proceeding for which such officer or director may be entitled to indemnificationhereunder shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of anundertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he is not entitledto be indemnified by the Corporation as authorized hereby.”

Furthermore,our bylaws provide for (i) indemnification of any person party to or threatened to be made party to any threatened, pending or completedaction, suit or proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of ours, or is or wasserving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise;(ii) payment or reimbursement by us of expenses incurred by any current or former officer or director in advance of the final dispositionof any such action, suit or proceeding; and (iii) our power to purchase insurance to protect any person who is or was a director, officer,employee or agent of ours, or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership,joint venture, trust or other enterprise.

Inaddition, we have entered into, and intend to continue to enter into, indemnification agreements with our directors and officers. Additionally,in accordance with our bylaws, we have acquired directors’ and officers’ insurance.

(a)During the past three years, in addition to the offer and sale of shares of our Common Stock to Cantor pursuant to the Purchase Agreement,we sold the following shares of Common Stock without registration under the Securities Act:

OnJune 1, 2021, we issued a $22.4 million convertible promissory note to PAVmed (the “Convertible Note”) in exchange for thecancellation of $22.4 million payable by us to PAVmed related to working capital advances and earned, but unpaid, management servicesfees. The Convertible Note had a maturity date of May 18, 2028, bore interest at a rate of 7.875% per annum and was convertible at theholder’s option into shares of our Common Stock at a conversion price of $1.42 per share, after adjustment for the 1.411-for-1stock split completed on October 6, 2021. As of October 15, 2021, PAVmed converted the outstanding principal amount of the ConvertibleNote into 15,803,200 shares of our Common Stock. The securities described in this paragraph were issued pursuant to the exemption fromregistration contained in Section 4(a)(2) of the Securities Act.

OnFebruary 25, 2022, together with our wholly owned subsidiary, LucidDx Labs Inc. (“LucidDx Labs”), we entered into an assetpurchase agreement (the “APA”) with ResearchDx, Inc. (“RDx”), and simultaneously closed the transactions contemplatedby the APA (the “Transactions”). Under the APA, LucidDx Labs acquired certain licenses and other related assets necessaryto operate a CLIA-certified, CAP-accredited clinical laboratory. As part of the consideration payable under the APA, subject to certainconditions, LucidDx Labs will pay up to $3,000,000 in cash or, in LucidDx Labs’ sole discretion, newly issued shares of our CommonStock, in quarterly installments of $250,000, pursuant to the terms of an earnout during the 36-month period commencing on February 25,2022. The shares of our Common Stock will be valued at fair market value as determined in accordance with the APA. In no event will theaggregate amount of our Common Stock issued pursuant to the APA exceed 19.99% of our issued and outstanding Common Stock as of February25, 2022. The securities described in this paragraph are being issued pursuant to the exemption from registration contained in Section4(a)(2) of the Securities Act.

Inaddition, during the past three years, we issued the following shares of our Common Stock to current and former directors, officers,employees and consultants of ours, under the exemption from registration for benefit plans and contracts relating to compensation asprovided under Rule 701 under the Securities Act: (i) 4,703 shares of our Common Stock upon the exercise of stock options and (ii) 1,947,795shares of our Common Stock subject to restricted stock awards (of which 7,055 shares were subsequently forfeited), in each case afteradjustment for the 1.411-for-1 stock split completed on October 6, 2021. The foregoing amounts do not include shares issued and issuablein connection with stock options and restricted stock awards that are registered under our registration statement on Form S-8 (File No.333-261807).

(a)The undersigned registrant hereby undertakes:

(1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)To include any prospectus required by section 10(a)(3) of the Securities Act;

(ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth inthe registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollarvalue of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximumoffering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changesin volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation ofRegistration Fee” table in the effective registration statement.

(iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement orany material change to such information in the registration statement;

Provided,however, That: Paragraphs (a)(1)(i), (ii), and (iii) of this section do not apply if the registration statement is on Form S-1, FormS-3, Form SF-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is containedin reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities ExchangeAct of 1934 that are incorporated by reference in the registration statement, or, as to a registration statement on Form S-3, Form SF-3or Form F-3, is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to bea new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemedto be the initial bona fide offering thereof.

(3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at thetermination of the offering.

(5)That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b)as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectusesfiled in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first usedafter effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registrationstatement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that ispart of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modifyany statement that was made in the registration statement or prospectus that was part of the registration statement or made in any suchdocument immediately prior to such date of first use.

(6)That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distributionof the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuantto this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securitiesare offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller tothe purchaser and will be considered to offer or sell such securities to such purchaser:

(i)Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule424;

(ii)Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to bythe undersigned registrant;

(iii)The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrantor its securities provided by or on behalf of the undersigned registrant; and

(iv)Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b)The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filingof the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, whereapplicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating tothe securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offeringthereof.

(h)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling personsof the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SECsuch indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event thata claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counselthe matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnificationby it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuantto the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-1 to be signedon its behalf by the undersigned, thereunto duly authorized, on June 16, 2022.

POWEROF ATTORNEY

KNOWALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Lishan Aklog, M.D. and Dennis M. McGrath his or hertrue and lawful attorney-in-fact and agent, with full power of substitution and revocation, for him or her and in his or her name, placeand stead, in any and all capacities, to execute any or all amendments including any post-effective amendments and supplements to thisRegistration Statement, and any additional Registration Statement filed pursuant to Rule 462(b), and to file the same, with all exhibitsthereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-factand agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to allintents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent,or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuantto the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-1 has been signed below by the followingpersons in the capacities and on the dates indicated.